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Introduction. In Italy, the transmission of measles is still 
endemic, and 7,919 cases were reported to the National Sur-
veillance System between January 2017 and December 2018. 
Aim of this study is to report the results of the measles surveil-
lance activities in the Metropolitan City of Milan from March 
2017 to December 2018, and to evaluate the surveillance per-
formance WHO indicators.
Methods. The Local Health Units (LHUs) carried out case 
investigations and collected specimens to send to the EpiSoMI 
Lab (Subnational Reference Laboratory, SRL) of the University 
of Milan for cases/outbreaks confirmation and genotyping per-
formed according to the WHO Guidelines.
Results. Overall, 610 suspected measles cases were reported by 
the surveillance system of the Metropolitan City of Milan. A total 
of 439 out of 540 cases with adequate specimens were laboratory-
confirmed by molecular and/or serological assays. Two-hundred 
and thirty-six cases were notified as sporadic and 203 as related 
to 94 outbreaks. The most confirmed cases were aged 15–39 
years, almost all not vaccinated. Overall, 282 cases were geno-
type D8 and 118 genotype B3.
The evaluation of a set of indicators to monitor the quality of sur-
veillance activities demonstrated the proficiency of the EpiSoMI 
Lab.
Conclusions. A well-done investigation of cases and outbreaks 
by the surveillance local system, in a timely manner, in order to 
notify and investigate suspected cases and to laboratory confirm 
or discard cases is fundamental to reduce morbidity, to prevent 
further virus transmission and to achieve measles elimination. 
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Introduction
Measles is a highly contagious disease caused by measles 
virus (Mv). Humans are the only reservoir of this infec-
tion and an effective vaccine is available. These charac-
teristics make this disease eradicable. The World Health 
Organization (WHO) planned to get the elimination of 
Mv, but the rapid succession of several measles outbreak 
in the European Region in the last years made this goal 
impossible to achieve in a short-term [1-3]. This is one 
of the leading immunization priorities of the European 
Region as outlined in the European Vaccine Action Plan 
2015-2020 [4]. Elimination of measles will depend on 
achieving high coverage and closing immunity gaps and 
ensuring high-quality, case-based surveillance [5, 6]. 
In Italy, the transmission of measles is still endemic, 
and 7,919 cases were reported to the National Surveil-
lance System between January 2017 and December 
2018 [7, 8], including eight deaths. The median age of 
the cases was 26 years, but the highest incidence was 
recorded in children under one year of age, too young 
to be vaccinated. The main settings involved were ho-
spital, family, school (included nursery and university), 
workplace and the community. In particular, numerous 
nosocomial outbreaks have been reported [9, 10], high-
lighting both the problem of low vaccination coverage 
among health workers (among which 450 cases were 
reported) and the need to implement protocols for the 
prevention of measles transmission in healthcare [11].
In Italy, the Measles and Rubella Surveillance Network 
(Mo.Ro.Net), consisting of one National Reference 
Laboratory (NRL) and 14 Subnational Reference Labo-
ratories (SRL) that meet rigorous standards to provide 
accurate results, was established in March 2017 [12]. 
Laboratories taking part in the network are required to 
participate in annual proficiency testing in selected tech-
niques and are evaluated through the WHO accreditation 
program. The Laboratory of the Coordinated Research 
Center for the Epidemiology and Molecular Surveil-
lance of Infections EpiSoMI (EpiSoMI Lab) of the Uni-
versity of Milan is one of the two SRL of the Lombardy 
Region (Northern Italy). The EpiSoMI Lab is a fully 
WHO-accredited laboratory and, from March 2017, set 
up a rapid and active surveillance for the complete char-
acterization of the Mv in the Metropolitan City of Milan 
and surrounding areas. 
A set of eight core indicators to monitor the quality 
of surveillance blend both field and laboratory activi-
ties [13]. Moreover, four of the eight indicators are di-
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rectly related to the management and the performance 
of the laboratory. These four indicators are the reporting 
rate of discarded non-measles non-rubella cases, the lab-
oratory confirmation, the viral detection, and the timeli-
ness of reporting laboratory results [14]. These standard 
performance indicators should be monitored to identify 
weakness in the laboratory surveillance system so that 
corrective action can be taken [15]. 
Aim of this study is to report the results of the measles 
surveillance activities in the Metropolitan City of Mi-
lan and surrounding areas from 1 March 2017 to 31 De-
cember 2018. Furthermore, we want to evaluate the four 
indicators, directly related to the management and the 
performance of the laboratory, in order to demonstrate 
whether the routine surveillance laboratory activities 
provide accurate and timely data. 
Methods
Epidemiological surveillance data
In Lombardy Region, according to the National Surveil-
lance Guidelines, all suspected measles cases must be 
promptly notified to the Local Health Units (LHUs). A 
suspected Mv case is defined as a subject with clinical 
evidence of “fever and rash” [6].
The LHUs carry out case investigations to determine 
source, risk factors and transmission settings, and con-
duct contact tracing to identify contacts, evaluate their 
immunity status, and vaccinate susceptible subjects. 
Moreover, LHUs collect specimens to send to the SRL 
for the case confirmation. 
Notified cases are systematically reported to the Lom-
bardy Regional database that provides, for each case, 
personal data, clinical details, all information collected 
during the epidemiological investigation as well as the 
SRL results including virus genotype. 
Descriptive information on measles cases in this study 
were obtained from the Lombardy Regional database.
Laboratory surveillance data
Specimen collection
Before collecting samples, informed consent was ob-
tained by suspected Mv cases (or their legal tutors in 
case of minors). Collection of adequate specimens, 
therefore, may include collection of specimens to test 
for virus-specific immunoglobulin M (IgM) (by Enzyme 
ImmunoAssay, EIA, on serum, blood or Dried Blood 
Spot, DBS) and for measles RNA detection [by Real-
time Reverse Transcription Polymerase Chain Reaction 
(RT-PCR) on urine and throat or nasopharyngeal swabs, 
Oral Fluid (OF)]. These biological samples must be col-
lected during the acute phase of the disease, specifically 
between 4 and 10 days after the exanthema onset (be-
tween 4 and 28 days for DBS) for serological test, up 
to 14 days for OF or up to 21 days for urine for virus 
detection using molecular techniques, or in any case at 
the first contact with medical care [13-16]. 
Measles virus-specific IgM detection
Blood, serum and DBS samples received for IgM analy-
sis were processed and tested as soon as possible after 
receipt in the laboratory. Serum samples were analyzed 
for serological testing using MV IgM capture Enzyme 
ImmunoAssay (EIA, Euroimmun AG, Luebeck, Germa-
ny), following the Manufacturing instructions.
Measles RNA detection
Total RNA was extracted from 1.5-15 ml of urine and/
or 0.2-1 ml of OF, depending on the timing of specimen 
collection, using the NucliSENS® easyMAG™ automat-
ed platform (bioMérieux bv, Lyon, France) according to 
the off-board lysis protocol. Extracted RNA was ana-
lyzed for molecular testing using a One-Step Real-time 
PCR targeting the hemagglutinin (H) gene, as previously 
described [17]. 
Measles genotyping
The genotype of Mv strains was identified by sequenc-
ing the highly variable region of the nucleoprotein gene 
(N-450) [18]. RT-PCR products were purified with the 
NucleoSpin® Gel and PCR Clean-Up (Macherey-Nagel 
GmbH & Co. KG, Germany), and nucleotide sequences 
were obtained by automated DNA sequencing based 
on fluorescent dye terminator on genetic analyzer ABI 
PRISM 3100 Genetic Analyser (Applied Biosystem, 
Thermo Fisher, USA). N-450 Mv sequences detected 
during the seasons 2017-2018 were analyzed using the 
Basic Local Alignment Search Tool (BLAST, http://
blast.ncbi.nlm.nih.gov/Blast.cgi) to identify similarities 
with previously reported strains and to define the be-
longing genotype. Virus genotypes were designated ac-
cording to the official WHO nomenclature and sequenc-
es have been submitted to the WHO’s MeaNS (Measles 
Nucleotide Surveillance) database [19, 20]. 
Laboratory confirmed case definition
A confirmed laboratory case was defined as a patient 
with serological and/or virological evidence of acute 
measles infection.
Indicators to monitor the quality of laboratory 
surveillance
The quality of laboratory surveillance and a sensitive 
system for detection and investigation of suspected cases 
of measles are evaluated by four performance indicators:
1. Reporting rate of discarded non-measles non-rubella 
cases: target: ≥ 2 cases per 100000 population per 
year. This indicator is calculated as the number of 
non-measles/non-rubella cases in a year divided by 
the average population in the studied area;
2. Laboratory confirmation: meaning the proportion of 
suspected cases with adequate specimens for detect-
ing acute measles infection collected and tested in 
a proficient laboratory (target: ≥ 80%). This indica-
tor is calculated as the proportion between the cases 
confirmed/discarded by each method of detection 
and the number of the suspected cases;
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3. Viral detection: meaning the proportion of laborato-
ry-confirmed chains of transmission (outbreaks) with 
samples adequate for detecting measles collected and 
tested in an accredited laboratory (target: ≥ 80%). 
This indicator reflects the fundamental contribution 
of the molecular characterization of the Mvs and is 
calculated as the percentage of all chains of transmis-
sion, identified during a calendar year, that have been 
successfully characterized by genetic analysis;
4. Timeliness of reporting laboratory results: meaning 
the proportion of results reported by the laboratory 
within 4 days of specimen receipt (target: ≥80%).
Statistical analysis
The comparison of two proportions was analyzed using 
the Chi square test. Two-sided p values < 0.05 were con-
sidered statistically significant. All analyses were con-
ducted using the OpenEpi software [21].
Results
Laboratory surveillance data
From March 2017 to December 2018, 610 suspected 
measles cases were reported by the surveillance system 
of the Metropolitan City of Milan and surrounding areas. 
For 540 (88.5%, 540/610) measles suspected cases were 
collected adequate specimens for serological and/or vi-
rological confirmation by the SRL. Of the 540 suspected 
cases, 80 (14.8%) had specimens only to be tested by 
molecular tests, whereas 6 (1.1%) only for serological 
evaluation. A total of 439 (439/540, 81.3%) reported 
cases were laboratory-confirmed by molecular and/or 
serological assays, in accordance with the WHO guide-
lines [12] (Fig. 1). The 59.2% (260/439) of confirmed 
cases tested positive by both serological and molecular 
assays; the 39.9% (162/439) was confirmed only by mo-
lecular tests, and the 3.9% (17/439) exclusively for anti-
Measles IgM (Tab. I).
In Figure 2 is described the number of confirmed and 
discarded cases by age groups and year of surveillance. 
During the considered period, the proportion of discard-
ed measles cases was 45.2% (38/84) for the age groups 
0-4 years, 17.9% (7/39) for the age groups 5-14 years, 
11.03% (32/290), 10.7% (12/112) and 75.0% (9/12) for 
the age groups 15-39, 40-64, and ≥ 65 years respectively. 
A statistical significance was found in the rate of dis-
carded non-measles cases of age groups 0-4 and ≥  65 
years (both p < 0.005).
Overall, 58.8% (258/439) of the confirmed cases (me-
dian age: 28 years; range: 1 day-7 years) were aged 15-
39 years, 22.8% (100/439) belonged to the 40-64 age 
group, 10.5% (46/439) were aged 0-4 years, and 3.4% 
were ≤ 1 year old. The 93.3% of confirmed cases were 
not vaccinated. During the considered period, the epide-
miologic investigation identified 94 different outbreaks/
chains of transmission: 77 during 2017 and 17 during 
2018 epidemic. The 53.76% of the confirmed cases was 
notified as sporadic.
Four-hundred and thirty-four out of 439 confirmed cases 
had adequate specimens for viral detection and 402 out 
of 434 (92.6%, 402/434) cases were genotyped. In 2 
subjects, vaccinated as susceptible during the epidemic 
period, was identified genotype A vaccine strain (0.5%). 
These subjects were excluded, since did not meet the 
case definition (genotype identification is required to 
distinguish wild type from vaccine strain if vaccinat-
ed within 21 days of rash onset). Two different geno-
types were identified, D8 and B3. Genotypes D8 and 
B3 have co-circulated during the whole period (Fig. 3). 
Fig. 1. Measles cases investigated during the period of surveillance activity to the enhanced measles surveillance system (data from the 
official data base of Lombardy Region) and cases confirmed by the SRL EpiSoMI, March2017-December 2018.
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The most common genotype was D8 (70.5%, 282/400 
cases), while B3 genotype was identified in the 29.5% 
(118/400) of cases. D8 genotype was mainly observed 
during 2017 epidemic (92.6%, 261/282), whereas during 
2018 the most circulating genotype was the B3 (76.4%, 
68/89). 
Overall, D8 genotype was identified in 277 (98.2%, 
277/282) autochthonous and 4 imported cases. In par-
ticular, 152 (53.9%, 152/282) were notified as sporadic 
cases, while 130 (46.0%, 130/282) were involved in 68 
outbreaks. B3 genotype was identified as imported in 13 
cases out of 118 (11.0%, 13/118), as imported-related 
in 1 case and as autochthonous in 105 (89.0%, 105/118) 
cases. Otherwise, epidemiological investigation notified 
61 (51.7%, 61/118) cases as sporadic and 57 (48.3%, 
57/118) cases as related to 24 outbreaks.
Indicators to monitor quality of laboratory 
surveillance
The four indicators to monitor the quality of laboratory 
surveillance are calculated by period (March 2017-De-
cember 2017 and January 2018-December 2018) and the 
results are shown in Table II.
The number of suspected cases that met the clinical case 
definition but were not laboratory confirmed was 60 dur-
ing 2017 and 39 during 2018. Considering a mean popu-
lation of 4000000 inhabitants included in the Metropoli-
tan City of Milan and surrounding areas, the reporting 
rate of discarded cases was about 1.5 per 100000 popu-
Tab. I. Reported suspected cases, suspected measles cases with adequate specimens and cases confirmation distribution during the study 
period (2017 and 2018).
Parameters 2017* 2018 Study period, N 
Reported suspected measles cases, N (%) 440 (72.1) 170 (27.9) 610 
Suspected measles cases with adequate 
specimens to be tested, N (%)
394 (73.0) 146 (27.0) 540 
Number of different 
specimen type 
investigated, n (%)
Serum/Blood/DBS 372 (68.9) 168 (31.1) 540
Urine 413 (69.3) 183 (30.7) 596
Oral fluid 405 (69.8) 175 (30.2) 580
Measles cases confirmed by lab, N (%) 335 (76.3) 104 (23.7) 439 
Assays used to confirm 
measles case (%)
Serological 11 (64.7) 6 (35.3) 17
Virological 125 (77.2) 37 (22.8) 162
Serological and virological 199 (76.5) 61 (23.5) 260
* in 2017 the parameters evaluation started on March.
Fig. 3. Genotypes circulation in the Metropolitan Area of Milan, from March 2017 to December 2018.
Fig. 2. Distribution by age groups for confirmed/discarded cases 
during surveillance activity of SRL EpiSoMI, March 2017- Decem-
ber 2018.
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lation per year in 2017 and about 1 per 100000 popula-
tion per year in 2018. 
In the considered period, more than the 80% of all cas-
es that met the clinical definition had the collection of 
adequate specimens and were laboratory confirmed/
discarded. Viral detection and genetic characterization 
of measles virus responsible of a chain of transmission 
was about 99% (only two chains of transmission were 
not genetically characterized). The 89.6% (484/540) of 
laboratory confirmed cases were reported to LHU by the 
laboratory within 4 days of specimen receipt. 
Discussion and conclusions
Monitoring progress toward measles elimination re-
quires high-quality case-based surveillance that is able 
to, in a timely manner, detect, notify and investigate 
suspected measles cases and outbreaks, correctly clas-
sify them as confirmed or discarded, and prevent further 
virus transmission [5, 22]. A key role of the high-quality 
case-based surveillance is represented by the laboratory 
activities.
In order to increase the performance level requested 
by the WHO, including timeliness and completeness 
of data, in March 2017 a sub-national network of ac-
credited laboratories for measles and rubella surveil-
lance (Mo.Ro.Net) coordinated by the NRL was formal-
ized [12, 23].
As SRL, EpiSoMI Lab undergoes regular and thorough 
processes for monitoring the accuracy and performance 
of its procedures and the operators who performing them 
(WHO accreditation). The EpiSoMI Lab must maintain 
that status for the forthcoming calendar year, thus the ac-
creditation assessment is based on the laboratory’s per-
formance during the preceding 12 months. EpiSoMI Lab 
achieved full accreditation for both investigated years, 
2017 and 2018.
In the Lombardy Region, from September 2013 to May 
2014 were collected biological samples from 80 sus-
pected cases and the 57.5% were laboratory confirmed. 
In that period, in Lombardy were noticed 880 suspected 
cases [24], while in 2016, 165 Mv cases were notified 
and 114 (69.1%) were confirmed (unpublished data). 
From March 2017 (date of Mo.Ro.Net establishing) 
to December 2018, a total of 959 Mv cases, including 
confirmed, possible and probable cases, were reported 
in Lombardy Region [25]. In particular, 610 out of 959 
Mv cases was related to a large measles outbreak in the 
Metropolitan City of Milan and surrounding areas, a 
highly populated area with about 4 million inhabitants. 
In this area, 439 measles cases (81.3% of cases investi-
gated) were laboratory-confirmed. This highlighted how 
a well-organized accredited laboratory improves the 
quality of the surveillance system. The laboratory needs 
adequate clinical samples to be timely and accurate in 
reporting confirmation/discard for clinically suspected 
cases. The detection of virus-specific IgM is the stand-
ard method for case confirmation. However, the use of 
RT-PCR for direct detection of measles specific RNA 
is fundamental to complement IgM antibody detection. 
Using PCR method has become necessary to perform a 
rapid case/outbreak investigation and to adopt the “fe-
ver and rash” case definition by collecting specimens at 
the first encounter with the healthcare system, and per-
forming molecular testing for virus detection in a “fast 
and aggressive” way [13, 26, 27]. Remarkably, with this 
strategy, the EpiSoMi Lab, during 2017-2018 period, 
have confirmed by molecular methods a relevant propor-
tion (13.2%) of seronegative cases (< 4 days from rash). 
These results prove the value of molecular analysis as 
tool to identify Mv cases otherwise unrecognized.
Overall, the 439 confirmed cases were classified by epi-
demiological investigations: 236 as sporadic cases and 
203 as related to 94 outbreaks. Four hundred cases were 
genotyped: 282 were genotype D8 and 118 were geno-
type B3. These two genotypes co-circulated in Europe 
during the study period [28]. 
A set of indicators was identified by the WHO [14] to 
monitor the quality of surveillance activities, including the 
reporting rate of discarded non-measles non-rubella cases 
(≥ 2 cases per 100000 population per year). The 88.57% 
of suspected Mv cases were laboratory confirmed with 
a reporting rate of discarded non-measles cases between 
1-1.5 per 100000 population in the two years, whereas at 
national level the reported rates were of 0.67 per 100000 
population per year in 2017 and of 0.37 per 100000 popu-
lation per year in 2018. The rate of discarded Mv cases 
were significantly higher in 0-4 years and ≥ 65 years age 
groups. These results could be explained by a higher at-
tention and sensitivity for pediatric population (at higher 
Tab. II. Indicators of the quality of laboratory surveillance. 
Laboratory indicators
Results
Target
March 2017 - December 2017 January 2018 - December 2018
1. Reporting rate of 
discarded non-measles 
non-rubella cases
1.5 cases per 100000 population 
per year
1 case per 100000 population 
per year
≥ 2 cases per 100000 population 
per year
2. Laboratory 
confirmation
89.5% 85.9% ≥ 80%
3. Viral detection 100% 97.4% ≥ 80%
4. Timeliness of 
reporting laboratory 
results
88.9% 92.4%  ≥ 80%
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risk of clinical complications, also neurological), and by a 
very low measles incidence in the elderly.
Another critical indicator of surveillance performance 
is the viral detection and genotyping (≥ 80% of labora-
tory-confirmed chains of transmission) [29]. The mean 
rate of genomic characterization performed during the 
observed period is 98.7%, much more than the national 
average (61.5% for 2017) [11]. The genetic characteriza-
tion has enabled us to identify or confirmed epidemio-
logical links. 
The evaluation of these indicators is intended to demon-
strate the proficiency of the accredited laboratories and 
whether adequate surveillance laboratory activities are 
implemented and documented for verification purposes. 
These data demonstrate that the EpiSoMI Lab has sup-
ported Mv cases ascertainment in the Lombardy Region 
in these two years of activity in Mo.Ro.Net in a profi-
cient way, confirming outbreaks/cases and determining 
Mv circulating genotypes. 
Achieving indicator targets provides assurance that pub-
lic health authorities can detect, locate and describe po-
tential Mv transmission in a timely manner [26].
In conclusion, a well-done investigation of cases and 
outbreaks by the surveillance local system, in order to 
notify and investigate suspected cases and promptly 
laboratory confirm or discard cases, is fundamental to 
reduce morbidity, to prevent further virus transmission 
and to achieve measles elimination. 
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